KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Dividends Paid - Common (2016 - 2018)

Teva Pharmaceutical Industries filings provide 10 years of Dividends Paid - Common readings, the most recent being -$2.0 million for Q4 2018.

  • On a quarterly basis, Dividends Paid - Common changed N/A to -$2.0 million in Q4 2018 year-over-year; TTM through Dec 2018 was $10.0 million, a 73.68% decrease, with the full-year FY2019 number at $52.0 million, up 420.0% from a year prior.
  • Dividends Paid - Common hit -$2.0 million in Q4 2018 for Teva Pharmaceutical Industries, down from $2.0 million in the prior quarter.
  • In the past five years, Dividends Paid - Common ranged from a high of $2.0 billion in Q4 2014 to a low of -$653.0 million in Q3 2017.
  • Median Dividends Paid - Common over the past 5 years was -$2.0 million (2018), compared with a mean of $228.9 million.
  • The widest YoY moves for Dividends Paid - Common: up 676.67% in 2017, down 904.62% in 2017.
  • Teva Pharmaceutical Industries' Dividends Paid - Common stood at $2.0 billion in 2014, then crashed by 43.38% to $1.2 billion in 2015, then increased by 29.35% to $1.5 billion in 2016, then plummeted by 143.71% to -$653.0 million in 2017, then skyrocketed by 99.69% to -$2.0 million in 2018.
  • The last three reported values for Dividends Paid - Common were -$2.0 million (Q4 2018), $2.0 million (Q3 2018), and -$2.0 million (Q2 2018) per Business Quant data.